세계의 방사성의약품 시장

Global Radiopharmaceuticals Market to Reach US$14.3 Billion by 2030

The global market for Radiopharmaceuticals estimated at US$7.6 Billion in the year 2024, is expected to reach US$14.3 Billion by 2030, growing at a CAGR of 11.0% over the analysis period 2024-2030. SPECT Radioisotopes, one of the segments analyzed in the report, is expected to record a 10.4% CAGR and reach US$6.2 Billion by the end of the analysis period. Growth in the PET Radioisotopes segment is estimated at 10.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.7 Billion While China is Forecast to Grow at 13.9% CAGR

The Radiopharmaceuticals market in the U.S. is estimated at US$3.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 13.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 8.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.0% CAGR.

Global Radiopharmaceuticals Market - Key Trends & Drivers Summarized

How Are Radiopharmaceuticals Revolutionizing Medical Imaging and Therapy?

Radiopharmaceuticals are transforming the field of medical imaging and therapy, providing advanced diagnostic and treatment options for various diseases, including cancer and cardiovascular conditions. These radioactive compounds are used in nuclear medicine to visualize, diagnose, and treat illnesses at the molecular level. Techniques such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) rely on radiopharmaceuticals to provide detailed images of the body's internal structures and functions. The precision and efficacy of radiopharmaceuticals enable early detection and targeted treatment, improving patient outcomes and reducing side effects compared to conventional therapies.

What Are the Technological and Regulatory Advances in Radiopharmaceuticals?

Technological advancements are significantly enhancing the development and application of radiopharmaceuticals. Innovations in radiochemistry and radiolabeling techniques are enabling the creation of more specific and effective compounds for various diagnostic and therapeutic applications. Advances in imaging technology, such as hybrid PET/MRI and PET/CT systems, are improving the accuracy and resolution of medical imaging. Regulatory frameworks are also evolving to support the safe and efficient development of radiopharmaceuticals. Agencies like the FDA and EMA are establishing guidelines and expedited pathways for the approval of novel radiopharmaceuticals, ensuring timely access to these cutting-edge medical treatments.

How Are Radiopharmaceuticals Impacting Oncology and Cardiology?

In oncology, radiopharmaceuticals are playing a crucial role in both diagnosis and therapy. They enable the detection of tumors at an early stage and monitor the effectiveness of treatment. Therapeutic radiopharmaceuticals, such as radiolabeled monoclonal antibodies, are used to deliver targeted radiation to cancer cells, minimizing damage to surrounding healthy tissue. In cardiology, radiopharmaceuticals are used to assess myocardial perfusion and viability, aiding in the diagnosis and management of coronary artery disease and other cardiac conditions. The ability to obtain precise diagnostic information and deliver targeted therapy is revolutionizing the management of these critical diseases.

What Factors Are Driving the Growth in the Radiopharmaceuticals Market?

The growth in the radiopharmaceuticals market is driven by several factors. The increasing prevalence of cancer and cardiovascular diseases is a major driver, as these conditions require advanced diagnostic and therapeutic solutions. Technological advancements in imaging and radiopharmaceutical development are enhancing the accuracy and efficacy of nuclear medicine procedures. Regulatory support and streamlined approval processes are facilitating the introduction of new radiopharmaceuticals. The growing adoption of personalized medicine is also boosting demand, as radiopharmaceuticals can be tailored to individual patient needs. Additionally, increasing investments in nuclear medicine research and the expansion of healthcare infrastructure are contributing to market growth. These factors collectively ensure the sustained growth and innovation in the radiopharmaceuticals market.

SCOPE OF STUDY:

The report analyzes the Radiopharmaceuticals market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters, Other Product Types); Application (Oncology, Cardiology, Endocrine Tumor, Neurology, Other Applications); End-Use (Hospitals, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 141 Featured) -

• Actinium Pharmaceuticals, Inc.
• Advanced Accelerator Applications
• Alliance Medical Ltd.
• Bayer HealthCare Pharmaceuticals
• Bracco Diagnostics, Inc.
• Cardinal Health, Inc.
• Curium US LLC
• GE Healthcare
• IBA Radiopharma Solutions
• Jubilant DraxImage Inc.
• Lantheus Medical Imaging Inc.
• Medi-Radiopharma Ltd.
• Nordion Inc.
• Radiopharm Theranostics Ltd.
• Siemens Healthcare GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Radiopharmaceuticals: A Prelude
  • Mechanism of Action
  • Global Economic Update
  • Hospitals Struggle as Distribution Bottlenecks Affect Supply of Medical Radioisotopes
  • Nuclear Medicine Services Back to Normal
  • Pandemic Presents Generational Opportunity
  • Global Market Outlook
  • Key Market Drivers
  • Market Restraints
  • Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
  • Classification of Radiopharmaceuticals
  • Diagnostic Radiopharmaceuticals: The Dominant Segment
  • Positron Emission Tomography (PET)
  • Single Photon Emission Computed Tomography (SPECT)
  • Therapeutic Radiopharmaceuticals
  • Supply Shortages Remain a Challenge to Market Growth
  • A Glimpse at Mo-99 Processors Worldwide
  • Nuclear Research Reactor Irradiators Worldwide: A Snapshot
  • Competition
  • Radiopharmaceuticals - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • Recent Market Activity
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Emergence of Radiotheranostics: Dual-Functioning Radiopharmaceuticals
  • Radiopharmaceuticals Become Promising for Cancer Theranostics
  • Changing Role of Radiopharmaceuticals in Diagnostic and Therapeutic Applications
  • Notable Clinical Applications of Radiopharmaceuticals in Nuclear Medicine
  • Advent of New Radiopharmaceuticals Widen Scope
  • Startups Develop Unique Radiopharmaceutical Solutions
  • Potential Role of Carbon Dots in Imaging and Theranostics
  • Nano Radiopharmaceuticals: Promising Role in Therapeutic and Imaging Applications
  • Current Major Focus Areas in Radiopharmaceutical Research
  • R&D Efforts in the Radiopharmaceuticals Market
  • Researchers Develop New Nanoparticles to Improve Radiopharmaceutical Efficiency
  • Oncoinvent and NPL Develop Unique Method to Measure & Deliver Dosages in Radiotherapy
  • Researchers Develop S-Value Database for Simplifying Complexity in Tumor Dosimetry
  • Key Impediments in Academic Research of Radiopharmaceuticals
  • Industry Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits
  • Role of Radiopharmaceuticals as Diagnostic Technology
  • Promising Molecular Imaging Technology Advancements for SPECT and PET
  • PET Eclipses SPECT in Cardiovascular Imaging
  • Worldwide Installed Base of Nuclear Imaging Equipment by Modality, PET Vs SPECT: 2023
  • Cardiac Amyloidosis Visualization: A Potential Application for PET
  • Innovative Radiopharmaceuticals to Boost Cardiac Applications
  • Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
  • Global Annual Medical Cost of Cardiovascular Diseases in US$ Billion (2010-2030)
  • Radiopharmaceuticals: Direct and Targeted Approach for Cancer Treatment
  • Increased Use of Radiopharmaceuticals Across Oncology to Drive Market Growth
  • Rising Cancer Incidence Worldwide Spurs Demand
  • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Intra-Operative Lymphatic Mapping (ILM) Creates New Opportunities for Radiopharmaceuticals in Cancer Detection
  • Growing Prominence of Therapeutic Radiopharmaceuticals for Cancer Care
  • Radiopharmaceuticals Expand Horizons for Cancer Treatment Arena
  • Radiopharmaceuticals as Potential Silver Bullet to Target & Treat Prostate Cancer
  • Challenges with Radiopharmaceuticals for Cancer
  • Rise in Incidence of Neurological Disorders to Drive Growth
  • Application of PET in Drug Development to Expand Opportunities
  • Personalized Medicine Drives Nuclear Medicine
  • Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population
  • Global Personalized Medicines Market (in US$ Billion) for the Years 2022, 2025 and 2028
  • Need for Guidance for Manufacture of Investigational Radiopharmaceuticals for Clinical Trials
  • Technetium-99m to Hold Immense Potential for Use in Diagnostic Nuclear Medicine in the Future
  • Shortage of 99Mo and 99mTc to Adversely Impact Provider Care and Patient Access
  • Novel Production Method Promises to End Problems of 99mTc Shortages
  • New Approach for Production of Clinical Radiopharmaceuticals
  • Gallium-68-labeled Radiopharmaceuticals: Production & Administering Challenges
  • Artificial Intelligence: A Promising Tool in Radiotherapy and Radiopharmaceuticals
  • Nuclear Medicine & AI to Power the Future of Precision Medicine
  • Aging Global Population: A Vital Demography
  • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • Rise in Healthcare Expenditure to Drive Growth
  • World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021 & 2023
  • Relevant Aspects of Radiopharmaceutical Production
  • Regulatory Regime Governing Production and Use of Radiopharmaceuticals
  • Challenges Facing Nuclear Medicine Industry
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for SPECT Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 2: World Historic Review for SPECT Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 3: World 14-Year Perspective for SPECT Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for PET Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 5: World Historic Review for PET Radioisotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 6: World 14-Year Perspective for PET Radioisotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Beta Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 9: World 14-Year Perspective for Beta Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Alpha Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Alpha Emitters by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 12: World 14-Year Perspective for Alpha Emitters by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 13: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 14: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 15: World 14-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 17: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 18: World 14-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 19: World Recent Past, Current & Future Analysis for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 20: World Historic Review for Cardiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 21: World 14-Year Perspective for Cardiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Endocrine Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 23: World Historic Review for Endocrine Tumor by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 24: World 14-Year Perspective for Endocrine Tumor by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 25: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 26: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 27: World 14-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 29: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 30: World 14-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 31: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 32: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 33: World 14-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 34: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 35: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 36: World 14-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 37: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 38: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 39: World 14-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2016, 2025 & 2030
  • TABLE 40: World Radiopharmaceuticals Market Analysis of Annual Sales in US$ Thousand for Years 2016 through 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Radiopharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 43: World 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2016, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • Market Overview
  • Increasing Incidence of Cancer: A Major Growth Driver
  • Estimated Number of New Cancer Cases in the US by Gender and Affected Site for 2023
  • Estimated Number of Cancer-Related Deaths in the US by Gender and Body Site for 2023
  • Estimated Number of New Cancer Cases in the US by State for 2023
  • Estimated Number of Cancer-Related Deaths in the US by State for 2023
  • Cardiovascular Imaging Drives Growth
  • Radiopharmaceuticals Usage Grows in PET Imaging
  • Radioisotope/Radiopharmaceuticals Supply Scenario
  • TABLE 44: USA Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 46: USA 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 49: USA 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 52: USA 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• CANADA
  • Market Overview
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 55: Canada 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 58: Canada 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 61: Canada 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• JAPAN
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • Market Overview
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 64: Japan 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 67: Japan 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 70: Japan 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• CHINA
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • Market Overview
  • TABLE 71: China Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 73: China 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 76: China 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 79: China 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• EUROPE
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • Market Overview
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 82: Europe 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 85: Europe 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 88: Europe 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 91: Europe 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2016, 2025 & 2030
• FRANCE
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 92: France Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 94: France 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 97: France 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 100: France 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• GERMANY
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 103: Germany 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 106: Germany 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 109: Germany 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• ITALY
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 112: Italy 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 115: Italy 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 118: Italy 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• UNITED KINGDOM
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 119: UK Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 121: UK 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 124: UK 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 127: UK 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• SPAIN
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 130: Spain 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 133: Spain 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 136: Spain 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• RUSSIA
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 139: Russia 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 142: Russia 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 145: Russia 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• REST OF EUROPE
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• ASIA-PACIFIC
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • Market Overview
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Radiopharmaceuticals by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2016, 2025 & 2030
• AUSTRALIA
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 169: Australia 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 172: Australia 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 175: Australia 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• INDIA
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • Market Overview
  • TABLE 176: India Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 178: India 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 181: India 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 184: India 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• SOUTH KOREA
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 187: South Korea 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 190: South Korea 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 193: South Korea 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• LATIN AMERICA
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 205: Latin America 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 208: Latin America 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 211: Latin America 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Radiopharmaceuticals by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 214: Latin America 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2016, 2025 & 2030
• ARGENTINA
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 217: Argentina 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 220: Argentina 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 223: Argentina 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• BRAZIL
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 226: Brazil 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 229: Brazil 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 232: Brazil 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• MEXICO
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 235: Mexico 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 238: Mexico 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 241: Mexico 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• MIDDLE EAST
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 253: Middle East 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 256: Middle East 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 259: Middle East 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Radiopharmaceuticals by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 262: Middle East 14-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2016, 2025 & 2030
• IRAN
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 265: Iran 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 268: Iran 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 271: Iran 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• ISRAEL
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 274: Israel 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 277: Israel 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 280: Israel 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• SAUDI ARABIA
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 292: UAE 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 295: UAE 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 298: UAE 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030
• AFRICA
  • Radiopharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Radiopharmaceuticals by Product Type - SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 310: Africa 14-Year Perspective for Radiopharmaceuticals by Product Type - Percentage Breakdown of Value Sales for SPECT Radioisotopes, PET Radioisotopes, Beta Emitters, Alpha Emitters and Other Product Types for the Years 2016, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Radiopharmaceuticals by Application - Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 313: Africa 14-Year Perspective for Radiopharmaceuticals by Application - Percentage Breakdown of Value Sales for Oncology, Cardiology, Endocrine Tumor, Neurology and Other Applications for the Years 2016, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Radiopharmaceuticals by End-Use - Hospitals, Diagnostic Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2016 through 2023 and % CAGR
  • TABLE 316: Africa 14-Year Perspective for Radiopharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostic Centers and Other End-Uses for the Years 2016, 2025 & 2030

IV. COMPETITION